dm+d

333711001

Articles

How should medicines be dosed in children who are obese?

28 May 2021Review on how to calculate medicine doses in children who are obese which includes a table on commonly prescribed medicines.

Safety in Lactation: Immunoglobulins

21 September 2020Immunoglobulins are considered to be compatible with breastfeeding and may contribute to the transfer of protective antibodies to the neonate.
Search Articles

Refrigerated Storage

SubgamBio Product Laboratory

Bio Product Laboratory
Subgam
160mg/mL solution for injection

Contact Bio Products Laboratory in all cases where a deviation from the recommended storage conditions has occurred. Refer to the current BNF for company contact details.

Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

15 October 2021
London MI Service

VigamBio Products Laboratory

Bio Products Laboratory
Vigam
5% w/v solution for injection

Contact Bio Products Laboratory in all cases where a deviation from the recommended storage conditions has occurred. Refer to the current BNF for company contact details.

Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

15 October 2021
London MI Service

GammanormOctapharma Limited

Octapharma Limited
Gammanorm
Solution for injection

In the event of an inadvertent temperature excursion the following data may be used:
The product may be stored below 25°C for up to 6 months (without exceeding the original expiry date). At the end of this period, the product should be discarded.

Contact Octapharma Limited in all cases where a deviation from the recommended storage conditions has occurred.

Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

Keep the product outside of the fridge if exposed to the conditions above
20 January 2022
London MI Service

OctagamOctapharma Limited

Octapharma Limited
Octagam
10% Solution for infusion

In the event of an inadvertent temperature excursion the following data may be used:

The product may be stored below 25°C for up to 9 months (without exceeding the original expiry date). At the end of this period, the product should be discarded.

Contact Octapharma Limited in all cases where a deviation from the recommended storage conditions has occurred.

Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

Keep the product outside of the fridge if exposed to the conditions above
20 January 2022
London MI Service

GamunexGrifols

Grifols
Gamunex
100 mg/mL solution for infusion

In the event of an inadvertent temperature excursion the following data may be used:
The product is stable for a one-off period of up to 6 months at room temperature (< 25°C). Subsequent refrigeration or freezing is not possible.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
Contact Grifols in cases where additional stability data is required. Refer to the current BNF for company contact details.

Reduce expiry date to 6 months if exposed to the conditions above. The new expiry date must be no later than the printed expiry date.
No if exposed to the conditions above
15 September 2021
London MI Service

Lactation Safety Information

HNIG; Immune globulin

HNIG; Immune globulin
Yes
Normal component of breast-milk
16 September 2020

New Medicines

Primary immunodeficiency

Information

New formulation
Biotest
Biotest

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Next generation polyvalent human normal immunoglobulin, manufactured using an innovative production process
In the UK over 4,300 people with PIDs have been registered on the UK Primary Immune Deficiency Registry to date. At present doctors estimate that about 5,000 people may be affected by a PID in the UK. The exact figure is unknown because there is no national screening programme for PIDs at birth [1].
Primary immunodeficiency
Intravenous infusion

HyQvia Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Information

HyQvia
Licence extension / variation
Takeda
Takeda

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

Liquid preparation of highly purified and concentrated immunoglobulin G (IgG) antibodies
CIDP is the most common chronic acquired demyelinating polyneuropathy. Prevalence rates vary between 1 and 7 per 100,000 people, but this may be an underestimation since the clinical presentation can be rather diverse, leading to under diagnosis [1].
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Subcutaneous infusion

HizentraDermatomyositis - first-line treatment or prevention in adults

Information

Hizentra
Licence extension / variation
CSL Behring
CSL Behring

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Human normal immunoglobulin contains mainly immunoglobulin G (IgG) with a broad spectrum of antibodies against infectious agents. Human normal immunoglobulin contains the IgG antibodies present in the normal population. It is usually prepared from pooled plasma from not fewer than 1,000 donors. It has a distribution of immunoglobulin G subclasses closely proportional to that in native human plasma.
Dermatomyositis is a connective tissue disease characterised by inflammation of skin and muscles. Few epidemiological studies have been published. One US study showed the incidence and prevalence of dermatomyositis to be 1.4 and 5.8 cases per 100,000 people respectively, with female preponderance and a higher prevalence among older age groups [1].
Dermatomyositis - first-line treatment or prevention in adults
Subcutaneous infusion